Abstract: The invention relates to the isolation of a nucleic acid molecule which encodes an esophageal cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen.

Abstract: The invention provides for the production of several humanized murine antibodies specific for the Lewis b antigen, which is recognized by the murine antibody 58-1066. The antigen is expressed on cell lines from colon, lung, bladder, breast, renal, pancreatic and ovarian cancers. The expression of the antigen is greatly increased in cancer tissues as compared to its expression in the corresponding normal tissue. The invention also provides for numerous polynucleotide encoding humanized Lewis b antigen specific antibodies, expression vectors for producing humanized Lewis b antigen specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis b antigen specific antibodies. Additionally, the invention provides methods of treating cancer using Lewis b antigen specific antibodies.

Abstract: The invention involves dimeric forms of the protein known as fibroblast activation protein alpha, or "FAP.alpha." and its uses.

Abstract: This invention relates to methods of producing synthetic GM2s. The methods are simple and efficient, and result in high yields of GM2s.

Abstract: This invention relates to isolated protein and to peptides which are found on the surface of colon cells and colon cancer cells, as well as to nucleic acid molecules encoding said protein and peptides. The protein and peptides bind to tumor-associated antibodies, such as mAb A33. The monomeric protein has a molecular weight of about 43 kD as determined by SDS gel electrophoresis under non-reducing conditions. In addition, this invention relates to the use of said nucleic acid molecules, protein, in monomeric or multimeric form, and to antibodies to said peptides in diagnostic, screening and therapeutic methods. This invention further relates to antibodies specific for said protein, in monomeric or multimeric form, and to antibodies to said peptides.

Abstract: The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule Melan-A, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of Melan-A and immunogenic compositions containing the molecules, and an adjuvant.

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.

Abstract: This invention provides a method of imaging a colorectal carcinoma lesion in a human patient which comprises administering to the patient a monoclonal antibody capable of binding to a cell surface antigen associated with the colorectal carcinoma lesion and which is labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface antigen, imaging any complex so formed, and thereby imaging the colorectal carcinoma lesion.This invention also provides a monoclonal antibody designated AS 33 (ATCC Accession No. HB 8779) and the hybridoma which produces it.

Abstract: An antigen which is specific to vascular endothelium is described. Described is a cell surface antigen which consists of four subunits; of 190, 145, 125 and 110 kd as determined by SDS-PAGE under reducing conditions as is a monoclonal antibody specific to this antigen. Uses, both diagnostic and therapeutic, are also described.

Abstract: The invention describes the identification and isolation of nucleic acid molecules which code for fibroblast activation protein alpha, or "FAP.alpha.". Various applications of the isolated molecules are also described.

Abstract: Monoclonal antibody 100-310 is found to be reactive against colon cancer cells and would therefore be useful for diagnostic imaging and treatment of colon cancer.

Abstract: The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.

Abstract: An antigen which is specific to vascular endothelium is described. Described is a cell surface antigen which consists of four subunits, of 190, 145, 125 and 110 kd as determined by SDS-PAGE under reducing conditions as is a monoclonal antibody specific to this antigen. Uses, both diagnostic and therapeutic, are also described.

Abstract: The invention is an isolated, sialylated glycoprotein, referred to as endosialin, which is expressed by tumor associated vascular endothelium and not normal vascular endothelium. The protein portion of the glycoprotein has a molecular weight of about 95 kilodaltons as determined by SDS-PAGE, and the glycoprotein has a molecular weight of about 165 kilodaltons, also as determined by SDS-PAGE. The oligosaccharides are linked by O-linkages to the protein. The glycoprotein is useful for making antibodies which are in turn used to identify tumor associated vascular endothelium.

Abstract: This invention provides a method of imaging a colorectal carcinoma lesion in a human patient which comprises administering to the patient a monoclonal antibody capable of binding to a cell surface antigen associated with the colorectal carcinoma lesion and which is labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface antigen, imaging any complex so formed, and thereby imaging the colorectal carcinoma lesion.This invention also provides a monoclonal antibody designated AS 33 (ATCC Accession No. HB 8779) and the hybridoma which produces it.

Abstract: The invention involves monoclonal antibodies which specifically bind to a cell surface antigen characteristic of tumor vascular endothelium. The antigen, referred to as endosialin, is a glycoprotein and has a molecular weight of about 165 kDa as determined by SDS-PAGE. The protein portion of the molecule has a molecular weight of about 95 kDa. Also disclosed are various uses of the monoclonal antibody and the antigen.

Abstract: Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis and differential diagnosis of prostate cancer.

Abstract: This invention provides a composition useful for diagnosing cancer which specifically recognizes a galactosyl-globoside. Preferably, the composition is a monoclonal antibody which specifically recognize the galactosyl-globoside antigen, gal-Gb4.Additionally, the present invention provides two hybridoma cell lines, designated J309 and D579, which produce monoclonal antibodies that specifically recognize gal-Gb4.The invention also provides a method of diagnosing a carcinoma which comprises contacting a sample from a human subject with a composition which specifically recognizes a galactosyl-globoside antigen and is labeled with a detectable moiety, under suitable conditions so as to form a detectable complex. The amount of formed complex is then quantified and correlated with values obtained from subjects devoid of carcinomas.

Abstract: The subject invention describes a method of determining the secretor status of an individual which comprises obtaining a sample of a biological fluid from the individual and determining whether the sample includes the Lewis.sup.a or Lewis.sup.b antigens, the presence of the Lewis.sup.a antigen in the sample indicating that the individual is a nonsecretor, the presence of the Lewis.sup.b antigen in the sample indicating that the individual is a secretor, and the presence of neither antigen indicating the secretor status of the individual is inconclusive. The invention also provides a method of further determining the secretor status of an individual of having an inconclusive secretor status which comprises determining whether the biological fluid sample from the individual includes A, B or precursor type 1 chain antigens, the presence of any such antigens in the sample indicating that the individual is a secretor, the lack of any such antigens in the sample indicating that the individual is a nonsecretor.

Abstract: This invention provides a method of imaging a colorectal carcinoma lesion in a human patient which comprises administering to the patient a monoclonal antibody capable of binding to a cell surface antigen associated with the coloretal carcinoma lesion and which is labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface antigen, imaging any complex so formed, and thereby imaging the colorectal carcinoma lesion.This invention also provides a monoclonal antibody designated AS 33 (ATCC Accession No. HB 8779) and the hybridoma which produces it.